for evaluation of possible NAION.
In terms of treatment decisions, the FDA recommends that clinicians consider discontinuing the GLP-1 RA in patients who develop NAION unless the benefits of the drug clearly outweigh the risk of continuing. People who have a history of NAION already face a higher risk of recurrence, so extra caution is warranted in this group. These points translate very directly into everyday pharmacy and clinic workflows. Pharmacists are in a position to ask about any prior history of NAION when initiating a GLP-1 RA and to